- Headquarters
- San Diego, California
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- avenzotx.com
- Total Funding
- $446.0M
- Last Round
- $60.0M Series BSep 2025
About
Avenzo Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation small-molecule and antibody-drug conjugate (ADC) therapies for oncology. Founded in 2022 by veterans of Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B in 2022), the San Diego-based company targets cancers with high unmet medical needs. The company has raised over $60M in Series B financing with backing from OrbiMed, Foresite Capital, SR One, NEA, Lilly Asia Ventures, Sands Capital, and others.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account